Analyst Research
| Report Title | Price |
|---|---|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Jefferson Research
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Enzon Pharmaceuticals, Inc. Announces Reduction In Workforce
Enzon Pharmaceuticals, Inc. announced that it is implementing a plan to reduce its workforce and operating costs to more closely align its resources with the Company`s research and development activities. The reduction in force will reduce the number of employees by approximately 48%, to a total of 47, effective June 2012. Enzon expects the reduction in force to result in approximately $6.0 million in reduced annualized operating expenses once the plan is fully implemented by the second quarter of 2012.
Latest Developments for Enzon Pharmaceuticals Inc
Latest Key Developments in Biotechnology
- Apricus Biosciences Inc Prices $17.1 Million Public Offering Of Common Stock And Warrants
- Stemline Therapeutics Inc Announces Exercise Of Option To Purchase Additional Shares
- Omeros Corp Announces Clearence Of New Drug Application By FDA For OMS824 In Huntington's Disease
- Miraca Holdings Inc Appoints Corporate Auditor
- Share this
- Link this
- Digg this


Follow Reuters